Citius Pharmaceuticals (CTXR) Competitors $2.19 +0.10 (+4.52%) Closing price 07/3/2025 03:57 PM EasternExtended Trading$2.18 -0.01 (-0.68%) As of 06:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. INCR, IGMS, IMUX, IZTC, IKNA, MNOV, ADAP, ICCC, VHAQ, and CLSDShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include InterCure (INCR), IGM Biosciences (IGMS), Immunic (IMUX), Invizyne Technologies (IZTC), Ikena Oncology (IKNA), MediciNova (MNOV), Adaptimmune Therapeutics (ADAP), ImmuCell (ICCC), Viveon Health Acquisition (VHAQ), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors InterCure IGM Biosciences Immunic Invizyne Technologies Ikena Oncology MediciNova Adaptimmune Therapeutics ImmuCell Viveon Health Acquisition Clearside Biomedical InterCure (NASDAQ:INCR) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and media sentiment. Do analysts prefer INCR or CTXR? Citius Pharmaceuticals has a consensus target price of $53.00, suggesting a potential upside of 2,314.58%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Citius Pharmaceuticals is more favorable than InterCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.80 Does the media refer more to INCR or CTXR? In the previous week, Citius Pharmaceuticals had 4 more articles in the media than InterCure. MarketBeat recorded 4 mentions for Citius Pharmaceuticals and 0 mentions for InterCure. InterCure's average media sentiment score of 0.00 beat Citius Pharmaceuticals' score of -0.33 indicating that InterCure is being referred to more favorably in the media. Company Overall Sentiment InterCure Neutral Citius Pharmaceuticals Neutral Which has preferable valuation & earnings, INCR or CTXR? InterCure has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInterCure$66.28MN/A-$18.32MN/AN/ACitius PharmaceuticalsN/AN/A-$39.14MN/AN/A Is INCR or CTXR more profitable? InterCure's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets InterCureN/A N/A N/A Citius Pharmaceuticals N/A -58.63%-37.67% Which has more risk & volatility, INCR or CTXR? InterCure has a beta of 1.18, suggesting that its share price is 18% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Do institutionals and insiders hold more shares of INCR or CTXR? 8.3% of InterCure shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 10.7% of Citius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. SummaryCitius Pharmaceuticals beats InterCure on 8 of the 13 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.33M$2.43B$5.53B$9.02BDividend YieldN/A1.78%5.22%3.99%P/E RatioN/A9.1527.7920.25Price / SalesN/A680.43426.06119.26Price / CashN/A21.7726.2128.59Price / Book0.214.558.045.65Net Income-$39.14M$31.26M$3.18B$249.15M7 Day Performance38.05%2.98%2.89%2.91%1 Month Performance157.93%3.46%1.67%4.11%1 Year Performance-83.41%0.77%34.53%20.98% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.422 of 5 stars$2.20+4.5%$53.00+2,314.6%-83.4%$23.33MN/A0.0020High Trading VolumeINCRInterCureN/A$1.47-1.3%N/A-35.4%$66.99M$66.28M0.00350Gap UpHigh Trading VolumeIGMSIGM Biosciences4.4129 of 5 stars$1.12+3.7%$5.50+391.1%-78.4%$66.95M$2.68M-0.34190IMUXImmunic2.9557 of 5 stars$0.70-0.4%$11.60+1,563.1%-32.5%$66.83MN/A-0.5770Positive NewsIZTCInvizyne TechnologiesN/A$10.39+6.8%N/AN/A$64.96MN/A0.0029Gap UpIKNAIkena Oncology2.3922 of 5 stars$1.34-1.5%$3.00+123.9%-19.9%$64.67M$9.16M-1.5670Positive NewsMNOVMediciNova1.8359 of 5 stars$1.31-1.5%$7.00+434.4%-10.6%$64.26M$1M-5.7010Gap DownADAPAdaptimmune Therapeutics2.1624 of 5 stars$0.24-2.2%$1.35+463.9%-79.4%$63.53M$179.64M-0.89490ICCCImmuCell0.2918 of 5 stars$6.96+3.1%N/A+56.9%$62.92M$26.49M-99.4170VHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeCLSDClearside Biomedical1.413 of 5 stars$0.80+3.9%$4.75+493.8%-35.8%$62.17M$3.76M-1.9530 Related Companies and Tools Related Companies INCR Competitors IGMS Competitors IMUX Competitors IZTC Competitors IKNA Competitors MNOV Competitors ADAP Competitors ICCC Competitors VHAQ Competitors CLSD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
